SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Biolase, Inc – ‘10-Q’ for 9/30/13 – ‘R13’

On:  Tuesday, 11/12/13, at 8:52am ET   ·   For:  9/30/13   ·   Accession #:  1564590-13-1200   ·   File #:  0-19627

Previous ‘10-Q’:  ‘10-Q’ on 8/9/13 for 6/30/13   ·   Next:  ‘10-Q’ on 5/12/14 for 3/31/14   ·   Latest:  ‘10-Q’ on 11/9/23 for 9/30/23

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

11/12/13  Biolase, Inc                      10-Q        9/30/13   65:8.2M                                   ActiveDisclosure/FA

Quarterly Report   —   Form 10-Q   —   Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-Q        Quarterly Report                                    HTML    543K 
 2: EX-4        Ex-4.2                                              HTML     65K 
 3: EX-4        Ex-4.3                                              HTML     63K 
 4: EX-10       Ex-10.4                                             HTML     47K 
 5: EX-31       Ex-31.1                                             HTML     27K 
 6: EX-31       Ex-31.2                                             HTML     28K 
 7: EX-32       Ex-32.1                                             HTML     21K 
 8: EX-32       Ex-32.2                                             HTML     22K 
64: R1          Document and Entity Information                     HTML     41K 
45: R2          Consolidated Balance Sheets                         HTML    136K 
42: R3          Consolidated Balance Sheets (Parenthetical)         HTML     48K 
17: R4          Consolidated Statements Of Operations And           HTML    105K 
                Comprehensive Loss                                               
44: R5          Consolidated Statements Of Cash Flows               HTML    144K 
31: R6          Basis of Presentation                               HTML     55K 
57: R7          Recent Accounting Pronouncements                    HTML     30K 
32: R8          Stock-Based Awards and Per Share Information        HTML    222K 
34: R9          Inventory                                           HTML     37K 
18: R10         Property, Plant, and Equipment                      HTML     53K 
33: R11         Intangible Assets and Goodwill                      HTML    101K 
56: R12         Accrued Liabilities and Deferred Revenue            HTML    110K 
52: R13         Lines Of Credit and Other Borrowings                HTML     55K 
43: R14         Commitments and Contingencies                       HTML     42K 
61: R15         Segment Information                                 HTML     56K 
55: R16         Concentrations                                      HTML     28K 
15: R17         Income Taxes                                        HTML     41K 
20: R18         Subsequent Event                                    HTML     22K 
60: R19         Accounting Policies (Policies)                      HTML    114K 
63: R20         Stock-Based Awards and Per Share Information        HTML    192K 
                (Tables)                                                         
65: R21         Inventory (Tables)                                  HTML     34K 
62: R22         Property, Plant, and Equipment (Tables)             HTML     49K 
47: R23         Intangible Assets and Goodwill (Tables)             HTML     93K 
19: R24         Accrued Liabilities and Deferred Revenue (Tables)   HTML    116K 
30: R25         Segment Information (Tables)                        HTML     47K 
23: R26         Basis of Presentation - Additional Information      HTML     67K 
                (Detail)                                                         
22: R27         Classification of Compensation Expense Associated   HTML     29K 
                with Share-Based Payments (Detail)                               
36: R28         Assumptions Used in Estimating Fair Value of Stock  HTML     32K 
                Options Granted (Detail)                                         
46: R29         Summary of Option Activity (Detail)                 HTML     72K 
53: R30         Cash Proceeds Along with Fair Value Disclosures     HTML     39K 
                Related to grants Exercises and Vesting Options                  
                (Detail)                                                         
27: R31         Stock Based Awards and Per Share Information -      HTML    115K 
                Additional Information (Detail)                                  
37: R32         Components of Inventory (Detail)                    HTML     32K 
59: R33         Inventory - Additional Information (Detail)         HTML     25K 
25: R34         Summary of Property, Plant, and Equipment (Detail)  HTML     36K 
50: R35         Property, Plant, and Equipment - Additional         HTML     22K 
                Information (Detail)                                             
51: R36         Intangible Assets Related to Accumulated            HTML     52K 
                Amortization and Goodwill (Detail)                               
38: R37         Intangible Assets and Goodwill - Additional         HTML     24K 
                Information (Detail)                                             
21: R38         Components of Accrued Liabilities (Detail)          HTML     43K 
49: R39         Changes In Initial Product Warranty Accrual and     HTML     38K 
                Expenses Under Initial and Extended Warranties                   
                (Detail)                                                         
26: R40         Summary of Deferred Revenue (Detail)                HTML     37K 
35: R41         Lines of Credit and Other Borrowings - Additional   HTML    111K 
                Information (Detail)                                             
54: R42         Commitments and Contingencies - Additional          HTML     32K 
                Information (Detail)                                             
29: R43         Summary of Net Revenue by Geographic Location       HTML     24K 
                (Detail)                                                         
48: R44         Segment Information - Additional Information        HTML     30K 
                (Detail)                                                         
41: R45         Concentrations - Additional Information (Detail)    HTML     31K 
24: R46         Income Taxes - Additional Information (Detail)      HTML     57K 
58: R47         Subsequent Event - Additional Information (Detail)  HTML     21K 
40: XML         IDEA XML File -- Filing Summary                      XML     91K 
16: EXCEL       IDEA Workbook of Financial Reports                  XLSX    134K 
39: EXCEL       IDEA Workbook of Financial Reports (.xls)            XLS   1.26M 
 9: EX-101.INS  XBRL Instance -- biol-20130930                       XML   1.59M 
11: EX-101.CAL  XBRL Calculations -- biol-20130930_cal               XML    132K 
12: EX-101.DEF  XBRL Definitions -- biol-20130930_def                XML    710K 
13: EX-101.LAB  XBRL Labels -- biol-20130930_lab                     XML    998K 
14: EX-101.PRE  XBRL Presentations -- biol-20130930_pre              XML    800K 
10: EX-101.SCH  XBRL Schema -- biol-20130930                         XSD    161K 
28: ZIP         XBRL Zipped Folder -- 0001564590-13-001200-xbrl      Zip    135K 


‘R13’   —   Lines Of Credit and Other Borrowings


This is an IDEA Financial Report.  [ Alternative Formats ]



 
v2.4.0.8
Lines Of Credit and Other Borrowings
9 Months Ended
Lines of Credit and Other Borrowings

NOTE 8—LINES OF CREDIT AND OTHER BORROWINGS

Lines of Credit

During the year ended December 31, 2012, the Company entered into and amended two revolving credit facility agreements with Comerica Bank (the “Credit Agreements”), which provide for borrowings against certain domestic accounts receivable and inventory, as set forth in the $4.0 million revolving credit facility agreement (the “Domestic Revolver”), and borrowings against certain export related accounts receivable and inventory, as set forth in the $4.0 million revolving credit facility agreement (the “Ex-Im Revolver”), for a combined aggregate commitment of borrowings up to $8.0 million. On May 7, 2013, the Company amended the Credit Agreements (“Amendment No. 2”) with Comerica Bank to increase the borrowing capacity under the Domestic Revolver from $4.0 million to $6.0 million, resulting in a combined aggregate commitment of borrowings up to $10.0 million. On September 6, 2013, the Company amended the Credit Agreements (“Amendment No. 3”) with Comerica Bank which decreased the borrowing capacity under the Domestic Revolver from $6.0 million to $4.0 million, resulting in a combined aggregate commitment of borrowings up to $8.0 million. The lines of credit mature on May 1, 2014, at which date any remaining borrowings and accrued interest under the lines of credit become due and payable. As of September 30, 2013, the Company had aggregate outstanding borrowings totaling approximately $5.5 million, which included $3.5 million under the Domestic Revolver and $2.0 million under the Ex-Im Revolver, as compared with aggregate outstanding borrowings totaling approximately $1.6 million as of December 31, 2012.

Lockbox arrangements under the revolving bank facilities provide that substantially all of the income generated is deposited directly into lockbox accounts and then swept into cash management accounts for the benefit of Comerica Bank. Cash is disbursed from Comerica Bank to the Company only after payment of the applicable debt service and principal. At September 30, 2013 and December 31, 2012, there were no restricted cash amounts. The Company’s obligations are generally secured by substantially all of the Company’s assets now owned or hereinafter acquired.

The outstanding principal balance of the Credit Agreements bears interest at annual percentage rates equal to the daily prime rate, plus 2.00% for the Domestic Revolver and 1.50% for the Ex-Im Revolver. The daily prime rate is subject to a floor of the daily adjusting LIBOR rate plus 2.50% per annum, or if LIBOR is undeterminable, 2.50% per annum. The Company is also required to pay an unused commitment fee of 0.25% based on a portion of the undrawn lines of credit, payable quarterly in arrears. During the three and nine months ended September 30, 2013, the Company incurred interest expense associated with the credit facilities of $181,000 and $381,000, respectively, including $71,000 and $152,000, respectively, of amortization of deferred debt issuance costs and $43,000 and $79,000, respectively, of amortization of the discount on lines of credit. During the three and nine months ended September 30, 2012, the Company incurred interest expense associated with the credit facilities of $98,000 and $133,000, respectively, including $38,000 and $53,000, respectively, of amortization of deferred debt issuance costs and $18,000 and $25,000, respectively, of amortization of the discount on lines of credit. Interest expense payable was approximately $9,000 and $19,000 at September 30, 2013 and December 31, 2012, respectively, and was included in accrued liabilities in the accompanying consolidated financial statements.

The Credit Agreements require the Company to maintain compliance with certain financial and non-financial covenants, as defined therein. Amendment No. 3 resulted in certain new and amended financial covenants for the quarters ending September 30, 2013 and December 31, 2013. As of September 30, 2013, the Company was in compliance with these covenants with the exception of the earnings before income tax, depreciation, and amortization (“EBITDA”) covenant. On November 8, 2013, the Company amended the Credit Agreements (“Amendment No. 4”) with Comerica Bank to waive the noncompliance with the minimum EBITDA covenant, reset the EBITDA covenant for the quarter ending December 31, 2013, and establish covenants for the remaining term of the agreements. Amendment No. 4 includes liquidity ratio and liquid asset covenants, and an equity raise requirement that established March 1, 2014 as the latest date the Company is required to raise at least $3.0 million. Any future noncompliance with these covenants may result in default interest rates and penalties, and Comerica Bank could declare the amounts outstanding immediately due and payable. Management is considering alternative financing solutions to mitigate any future liquidity constraints this may impose on the Company. 

During the year ended December 31, 2012, the Company issued and amended a warrant to Comerica Bank (“2012 Comerica Warrant”) to purchase up to 80,000 shares of the Company’s common stock at an amended exercise price per share of $2.00. During the three months ended March 31, 2013, Comerica Bank exercised all 80,000 of the 2012 Comerica Warrant shares on a cashless basis pursuant to the Notice of Exercise resulting in a net issuance of 40,465 shares of common stock.

On September 6, 2013, the Company issued an additional warrant to Comerica Bank (the “September 2013 Comerica Warrant”) to purchase up to 100,000 shares of the Company’s common stock at an exercise price per share of $2.00. The September 2013 Comerica Warrant vests in four equal quarterly tranches commencing on December 31, 2013 and shares are exercisable once vested. The 2013 Comerica Warrant may be exercised with a cash payment from Comerica Bank, or, in lieu of a cash payment, Comerica Bank may convert the warrant shares into a number of shares, in whole or in part. These warrant shares will expire if unexercised on September 6, 2018. The fair value of the September 2013 Comerica Warrants was estimated using the Black-Scholes option-pricing model with the following assumptions: expected term of 5.00 years; volatility of 105.32%; annual dividend per share of $0.00; and risk-free interest rate of 1.77%; and resulted in an estimated fair value of $143,000 which was recorded as equity and resulted in a discount to the credit facilities at issuance. The discount is being amortized on a straight-line basis to interest expense over the remaining term of the Credit Agreements.

In connection with Amendment No. 4, the Company incurred an amendment fee of $10,000 and issued an additional warrant to Comerica Bank (the “November 2013 Comerica Warrant”) to purchase up to 100,000 shares of the Company’s common stock at an exercise price per share of $2.00. The November 2013 Comerica Warrant includes an accelerated vesting clause that may be triggered by certain events described therein, but otherwise vests in four equal quarterly tranches commencing on December 31, 2013, and shares are exercisable once vested. The November 2013 Comerica Warrant may be exercised with a cash payment from Comerica Bank, or, in lieu of a cash payment, Comerica Bank may convert the warrant shares into a number of shares, in whole or in part. These warrant shares will expire if unexercised on November 8, 2018.

Other Borrowings

The Company finances a portion of its annual insurance premiums which it pays in installments over nine months. As of September 30, 2013 and December 31, 2012, $0 and $379,000 at an annual interest rate of 3.0%, respectively, was outstanding under this arrangement and was included in accrued liabilities in the accompanying consolidated financial statements. The Company incurred interest expense associated with the financed insurance premiums of approximately $1,000 and $5,000 during the three and nine months ended September 30, 2013, respectively, and approximately $0 and $4,000 during the three and nine months ended September 30, 2012, respectively.


Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘10-Q’ Filing    Date    Other Filings
9/6/18
5/1/14
3/1/14
12/31/1310-K,  10-K/A,  SD
Filed on:11/12/138-K
For Period end:9/30/13
9/6/138-K,  8-K/A
5/7/138-K
3/31/1310-Q
12/31/1210-K
9/30/1210-Q
9/15/09
 List all Filings 
Top
Filing Submission 0001564590-13-001200   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Wed., May 1, 6:12:34.1am ET